Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online: Letters

Home > PJ  > Letters

Return to PJ Online Home Page

The Pharmaceutical Journal Vol 266 No 7149 p718-722
May 26, 2001

Letters

  RPM
  Packaging
  Disillusioned youth
  GlaxoSmithKline
  Interactions
  Travel medicine
  Seprate register
  Code of Ethics


Letters to the Editor

Interactions

Take care with Zyban

From Mr Anthony Cox, MRPharmS, Mr Christopher Anton, MA MEng, and Dr Robin Ferner, MD FRCP

The summary of product characteristics for amfebutamone (bupropion, Zyban), marketed by GlaxoSmithKline, advises that caution should be taken when using amfebutamone with certain other groups of medication. These are:

  • Drugs that lower seizure threshold or have been associated with seizures.
  • Drugs that affect cytochrome P450 isoenzyme CYP 2B6 (the major enzyme responsible for the metabolism of amfebutamone).
  • Enzyme inhibitors.
  • Enzyme inducers.
  • Drugs that are metabolised by cytochrome P450 isoenzyme CYP 2D6 (which amfebutamone inhibits).

At a recent inquest into the death of a patient prescribed amfebutamone in combination with chloroquine and diphenhydramine, the coroner said that advice given when prescribing amfebutamone should be improved. In order to help prescribers and pharmacists to avoid potential interactions with amfebutamone and drugs seen in the community, we have made a provisional list of those drugs that might interact (PDF *). Amfebutamone has potentially serious interactions with many drugs. Co-prescription with those which lower the seizure threshold is a relative contra-indication, and care is also needed when metabolic interactions are possible.

Anthony Cox
Christopher Anton
Robin Ferner

West Midlands Centre for Adverse Drug Reaction Reporting
Birmingham

 

* PDFs require Acrobat Reader 4 or later. Click here for the latest version

Back to Top

Previous Topic (GlaxoSmithKline)
Next Topic (Travel medicine)
Send your letter to The Editor



©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20004356

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.